Á lódáil...
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
CONTEXT: Approximately 10% to 20% of prolactinomas are resistant to dopamine agonist therapy. The ErbB signaling pathway may drive aggressive prolactinoma behavior. OBJECTIVE: We evaluated lapatinib, an ErbB1-epidermal growth factor receptor (EGFR)/ErbB2 or human EGFR2 (HER2) tyrosine kinase inhibit...
Na minha lista:
| Foilsithe in: | J Clin Endocrinol Metab |
|---|---|
| Main Authors: | , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Oxford University Press
2020
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7823257/ https://ncbi.nlm.nih.gov/pubmed/33150390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgaa805 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|